Articles related to KIDNEY CANCER/RCC

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.

In the KEYNOTE-564 trial, adjuvant pembrolizumab demonstrated a significant improvement in disease-free survival among patients with renal-cell carcinoma at high risk of recurrence after nephrectomy, offering a new direction in post-surgical treatment strategies.

In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

Belzutifan’s FDA approval, following the LITESPARK-005 trial results, represents a significant stride in treating advanced kidney cancer, offering a novel therapeutic option for patients who have exhausted standard treatments.

A recent study from Fox Chase Cancer Center has revealed that as many as 23% of cystic renal masses may carry high-grade, or aggressive, disease. This finding challenges the prevailing assumption of their low-risk nature and underscores the need for more discerning diagnostic and treatment strategies.